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needs to be taught in small friendly doses tied to practical problems. Each analysis 
note presented by Doug Gause has sketches drawn by artist Pat Gause.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Study Design
PMC48
METHODS FOR IDENTIFYING CASE REPORTS OF SUSPECTED ADVERSE 
DRUG REACTIONS: AN EVALUATION OF THE EFFICIENCY OF 
ALTERNATIVE SEARCH STRATEGIES IN MEDLINE AND EMBASE
Michels SL, Ward A, Jones N
United BioSource Corp., Lexington, MA, USA
To illustrate the precision and sensitivity of identifying case reports of adverse events 
(AE) in MEDLINE and EMBASE, eight searching methods were created and applied 
to two systematic reviews of case reports. Search methods included use of indexing 
and text words for synonyms of AE and related terms, as well as drug, disease and 
study design. All eight methods contained the drug and combinations of other search 
strings and ranged from broad to very speciﬁc. Searches were developed for MEDLINE 
and EMBASE; duplicates were removed. Results from each approach were checked 
against a “gold standard” (GS) of case reports previously identiﬁed in two systematic 
reviews (75 anti-TNF agent, 57 baclofen case reports). Sensitivity and precision of 
each method were calculated. The broadest search, using drug terms alone, yielded 
over 11,000 and over 3,600 references for each systematic review topic. Sensitivity 
decreased as search methods became narrower; precision was consistently low (gener-
ally <6%). The search method for drug terms alone had 100% sensitivity for both 
systematic review topics with very low precision (<1.6%). Precision was highest when 
drug, disease, case report and AE were combined for baclofen (15%) with low sensitiv-
ity (26%). Of the GS articles available from MEDLINE, 7% and 18% of anti-TNF 
agent and baclofen case reports respectively were not indexed as case reports. Sensitive 
search methods able to identify relevant case reports are important, but when a sensi-
tive search was constructed, this lead to low precision. A sensitive search method must 
be broad, and search both databases. Precision remains low with each combination 
of approaches, making accurate identiﬁcation of case reports rather labor intensive. 
This illustration demonstrated the extent to which decisions made when developing 
search methods impact the comprehensiveness of reviews. Further work is on-going 
to conﬁrm the generalizability of these ﬁndings to other drugs.
CANCER – Clinical Outcomes Studies
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USE OF WHITE BLOOD CELL GROWTH FACTORS AND RISK OF 
ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES 
AMONG ELDERLY NON-HODGKIN’S LYMPHOMA PATIENTS
Gruschkus SK1, Lairson D2, Dunn JK3, Risser JM3, Du XL3
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OBJECTIVES: Therapy-related myelodysplastic syndromes and acute myeloid leuke-
mia (t-MDS/AML) are devastating long-term complications of cancer therapy. Evi-
dence suggests that white blood cell growth factors (CSFs) may increase risk of t-MDS/
AML among patients (pts) receiving chemotherapy, possibly because they stimulate 
the proliferation and differentiation of hematopoietic stem cells and also interfere with 
apoptosis. The purpose of this retrospective study was to evaluate the association 
between CSF use and t-MDS/AML among a large population-based cohort of elderly 
non-Hodgkin’s lymphoma (NHL) pts treated with chemotherapy. METHODS: NHL 
pts were identiﬁed from the Surveillance, Epidemiology, and End Results-Medicare 
database diagnosed from 1992 to 2002 who received chemotherapy within 12 months 
of diagnosis. Pts were followed from their initial chemotherapy until t-MDS/AML 
development, death, or end of study period (December 31, 2006). Kaplan-Meier and 
Cox proportional hazards analyses were used to evaluate the association between CSF 
use and t-MDS/AML. RESULTS: A total of 13,203 pts were identiﬁed. Overall, 40% 
(n = 5,266) received CSF. 272 (5.2%) pts receiving CSF developed t-MDS/AML vs. 
230 (2.9%) who did not receive CSF (log-rank p < 0.0001). In a multivariable Cox 
regression analysis adjusting for gender, histology, stage, comorbidities, chemotherapy 
dates, and chemotherapy agent, CSF use was independently associated with a 53% 
increased risk of t-MDS/AML (HR 1.53; 95% CI 1.26–1.84). A dose-response rela-
tionship was observed, with t-MDS/AML risk increasing by quartile of CSF claims. 
In an evaluation of plausible biologic interactions, we found that pts receiving CSF 
and antimetabolite chemotherapy (n = 1,567 pts) had a 2.5 fold increased risk of 
t-MDS/AML (HR 2.49; 95% CI 1.91–3.26) vs. pts who received neither agent (p-inter-
action = 0.04). CONCLUSIONS: Our ﬁndings suggest that CSF use among elderly 
NHL chemotherapy pts chemo may increase risk of t-MDS/AML, even though abso-
lute risk is low. Future studies are necessary to verify these results and to determine 
the clinical implications of the observed interaction between CSF use and antimetabo-
lite chemotherapy.
PCN2
DIABETIC MEDICATIONS AND ITS ASSOCIATION WITH MORTALITY 
IN HOSPITALIZED CANCER PATIENTS
Nowshad G1, Alam S2, Shah P3, Salahudeen A4
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OBJECTIVES: The effect of diabetes and diabetic medications on the morbidity and 
mortality in hospitalized cancer patients is a serious concern. We examined the asso-
ciation of diabetic medications with the transfer to ICU and inpatient mortality. 
METHODS: Electronic patient records were prospectively collected in 5489 hospital-
izations to UT MD Anderson Cancer Center from May 1st, to July 31st, 2006. For 
each patient demographic, laboratory and pharmacy data were obtained. To observe 
the effect of diabetic medications, we selected only diabetic patients, which were 
36.3% (1991) of the total hospitalization. Descriptive and logistic regression analyses 
were performed. RESULTS: Out of 1991 hospitalizations for diabetic cancer patients, 
ﬁfty seven percent were male, sixty nine percent were White with median age of sixty 
one. These patients were on different diabetic medications and thirty one percent were 
only on sliding scale insulin (SSI).After controlling for socio-demographic variables 
and other medications like chemotherapy, we found cancer patients who were only 
on SSI were more likely to be transferred to intensive care unit (ICU), (OR 2.31, CI: 
1.7–3.2; P < 0.001) and die during hospitalization (OR 1.88, CI: 1.3–2.7; P < 0.001). 
Glucocorticoids administration was also signiﬁcantly associated with inpatients mor-
tality (OR 5.91, CI: 3.5–9.8; (p < 0.00)). CONCLUSIONS: We found strong associa-
tions between the method of administration of insulin (SSI) and transfer to ICU and 
inpatient mortality in cancer patients with diabetes. Drug dosage and administration 
in inpatient settings should be tailored to the need of the patients to optimize the 
medication effect and minimize the side effects.
PCN3
RELIABILITY OF CLINICIAN VS. CLINICIAN ADVERSE SYMPTOM 
REPORTING
Atkinson TM1, Sit L1, Coffey C2, Shaw M1, Fruscione M1, Lavene D1, Gönen M1, Li Y1, 
Basch E1
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 2University of Kansas 
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OBJECTIVES: Adverse symptom reporting is essential in clinical trials and drug label-
ing to assess and ensure patient safety. The standard approach to collecting adverse 
symptoms in cancer trials is clinician reporting using the Common Terminology 
Criteria for Adverse Events (CTCAE), which rates symptoms based upon descriptive 
clinical criteria. Despite the importance of this information, the reliability of these 
ratings has not been veriﬁed. At Memorial Sloan-Kettering Cancer Center, patients 
are routinely evaluated via CTCAE items by a clinician in an ofﬁce suite, and again 
shortly thereafter by a second clinician in a chemotherapy suite, with no information 
passed between clinicians. METHODS: To measure the reliability of these evaluations, 
a retrospective analysis of medical charts was completed in a sample of 433 patients 
aged 26–91 (M = 62.39; 41.8% male) receiving chemotherapy, who were enrolled in 
an observational study conducted between March 2005 and August 2009. Cancer 
diagnoses included lung (N = 153), prostate (N = 127), and gynecologic (N = 153). 
RESULTS: For the ﬁrst post-chemotherapy visit, intraclass correlation coefﬁcients 
were moderate for fatigue (0.52), dyspnea (0.75), nausea (0.55), vomiting (0.50), 
diarrhea (0.63), constipation (0.48) and neuropathy (0.73). The average time between 
evaluations was 70.42 minutes (range 67.97–72.88). These values were stable over up 
to six subsequent visits and did not differ based on age, gender, or elapsed time 
between evaluations. CONCLUSIONS: Given the short period of time and lack of 
interventions between reporting time points, the most likely cause of this lower than 
expected agreement between different clinicians is limited reliability of clinician report-
ing of this information. This ﬁnding has implications to clinical trials, as it brings into 
question the reliability or accuracy of symptom safety information. The investigators 
are currently evaluating patient-reported outcomes as an alternative and potentially 
more reliable method for collecting this information.
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INSULINS AND RISK OF CANCER AMONG TYPE 2 DIABETICS:  
A SYSTEMATIC REVIEW
Lu Z, Weiss Smith S
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: There have been reports which suggest that insulin glargine use may 
contribute to increased cancer risk in some type 2 diabetic populations, in addition 
to the fact that diabetes mellitus is also associated with certain types of cancer. There-
fore, the objective of the present study is to conduct a review of published studies on 
insulins and the risk of cancer in patients with type 2 diabetes and summarize the 
ﬁndings. METHODS: Several databases such as Medline and PubMed were used for 
publication searching. Key words included insulin, tumor, cancer, type 2 diabetes, and 
speciﬁc insulin names such as glargine, lantus, lispro, aspart, etc. Only English lan-
guage literature was considered for articles looking at the increased risk of cancer 
among type 2 diabetic patients using insulins. RESULTS: About 30 articles were 
selected, among those, 4 studies were conducted in humans using secondary database. 
All were historic cohort studies, and three used Cox regression for analysis. Two 
articles established a positive association between cancer incidence and insulin 
glargine, while the other two found no association. Three studies also showed that 
several insulins other than glargine are not associated with an increased risk of cancer. 
A24 Abstracts
Limitations of these studies include failure to control for important confounders, small 
sample size and short study period, which may have impact on the risk of cancer. 
CONCLUSIONS: Given the fact that cancers are rare and often take a long time to 
develop, further studies require very large population with long follow up time to have 
sufﬁcient power to detect a possible effect. This, combined with small proportion of 
insulin users who were exposed to glargine, may be a reason to studies that found no 
association, which leaves a question of a class effect. Future studies to explore the 
effect of all other insulins and the possible mechanism may help to untangle this 
question.
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ASSESSMENT OF NEUROPATHY IN CLAIMS DATA AND THE 
ASSOCIATION WITH DOCETAXEL (DC) AND PACLITAXEL (PC) IN 
ADJUVANT BREAST CANCER (BC)
Burke JP1, Seal B2, Teitelbaum A3, Henk HJ1
1i3 Innovus, Eden Prairie, MN, USA, 2Sanoﬁ-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 
3i3 Global, San Diego, CA, USA
OBJECTIVES: Neuropathy, a common side effect of taxanes, is often dose-limiting 
and may result in changes in treatment. This study examined the occurrence of neu-
ropathy in claims data from commercially insured US patients with BC treated with 
adjuvant DC or PC. METHODS: This retrospective database analysis used eligibility, 
medical and pharmacy claims data from a large US health care organization, including 
subjects with a claim for BC and a claim for DC or PC-containing chemotherapy from 
1/1/98–12/31/05. Subjects were stratiﬁed by dosing interval (weekly (qw) or Q 21 days 
(q3w)). Neuropathy was deﬁned using ICD-9-CM codes 356.4, 356.8, 356.9, 357.2, 
357.4, 357.5, 357.6, 357.7, 357.8x, 357.9, 377.34, 354.4, 354.5, 354.8, 354.9, 
355.7x, 355.8 and 355.9. Neuropathy grade could not be assessed by claims data. 
Subjects were followed until the earliest of date of death or last enrollment or 
12/31/06. Chi-square was used to compare descriptive variables. Logistic regression 
(LR) was used to examine the independent association of index medication and 
neuropathy. Covariates included age, geographic region, baseline co-morbidity score 
and use of medications for neuropathy. RESULTS: A total of 3619 subjects were 
identiﬁed for PC (n = 329, qw; 1685, q3w) or DC (n = 204, qw; 1045, q3w). A sig-
niﬁcantly lower frequency of neuropathy was seen in the follow-up period for DC-
based treatments compared to PC (7.0% vs 10.6%, p < 0.001). Differences were also 
noted when stratifying by dosing interval (6.7% vs 10.0%; p = 0.003 in q3w, 9.3% 
vs 13.7%; p = 0.061 in qw). After adjusting for covariates, the odds of neuropathy 
remained signiﬁcantly lower with DC-based treatment (OR = 0.70, CI = 0.559, 0.920; 
p = 0.010). CONCLUSIONS: Less neuropathy was noted with DC-based treatment 
compared to PC. This difference persisted with stratiﬁcation by dosing interval. The 
lower occurrence of neuropathy with DC may favor maintenance of dose intensity.
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EVALUATION OF THE RELIABILITY OF ELECTRONIC MEDICAL 
RECORD DATA IN IDENTIFYING COMORBID CONDITIONS AMONG 
PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC)
Gruschkus SK1, Hoverman JR2, Muehlenbein CE3, Forsyth M4, Chen C1, Lopez W1, 
Lawson AH5, Pohl G3
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OBJECTIVES: Traditional methods for identifying comorbidities in retrospective 
observational research have relied primarily on claims data. The purpose of this study 
was to validate a 2-phased strategy to search EMR data to identify comorbidities 
among cancer patients. METHODS: Advanced stage NSCLC patients (N = 2513) who 
received chemotherapy from July 1, 2006–June 30, 2008 were identiﬁed using 
iKnowMed, US Oncology’s proprietary oncology-speciﬁc EMR system. EMR data 
were searched for documentation of the following comorbidities: moderate/severe 
renal disease, congestive heart failure (CHF), dementia, chronic obstructive pulmonary 
disease (COPD), cerebrovascular disease, paralysis, diabetes, peripheral vascular 
disease (PVD), myocardial infarction (MI), liver disease, and AIDS. The search was 
conducted in 2 phases. Initially, a series of programmatic queries were conducted to 
search standardized information on concomitant illnesses, patient history, review of 
systems, and diagnoses other than cancer. In a second phase, keyword searches of 
text-based ﬁelds (i.e., physician dictation notes, problem lists, etc.) were conducted. 
To evaluate the validity of the comorbidity information derived from the EMR, we 
randomly sampled 450 patients for whom we found no documentation of comorbidi-
ties using our 2-phased approach. We then exhaustively scanned available claims data 
and conducted comprehensive chart reviews to conﬁrm that these patients did not 
have any of the comorbidities of interest. Negative predictive values (true negatives / 
(true negatives + false negatives) were calculated. RESULTS: Using our 2-phased 
search of the EMR, we found an overall prevalence of comorbidities of 22%. The 
most commonly identiﬁed conditions were COPD, diabetes, PVD, and CHF. Among 
the random sample of 450 patients for whom no comorbidities were identiﬁed, we 
identiﬁed 36 who had evidence of comorbidities after scanning claims data and con-
ducting chart reviews (negative predictive value = 0.92). CONCLUSIONS: Results of 
this study suggest that efﬁcient queries of EMR data may provide reliable data on 
comorbid conditions among cancer patients.
PCN7
A COMPARISON OF INTRAVENOUS AND ORAL FORMULATIONS OF 
FLUDARABINE IN THE TREATMENT OF CHRONIC LYMPHOCYTIC 
LEUKEMIA
Eaddy M1, Chen L2, DuBois R1, Davies EH3
1Xcenda, Palm Harbor, FL, USA, 2Sanoﬁ-Aventis, Bridgewater, NJ, USA, 3Xcenda, Charlotte, 
NC, USA
OBJECTIVES: Fludarabine (F) has been proven to be highly effective in the treatment 
of chronic lymphocytic leukemia (CLL). Both oral and IV F are used internationally. 
Recently, the oral formulation of ﬂudarabine was approved in the US for treating 
CLL, which may offer advantages for providers, payers and patients. This study is a 
systematic review of clinical trial and retrospective data for oral and IV ﬂudarabine, 
focusing on differences in efﬁcacy, complications, resource utilization, cost and patient 
preference. METHODS: PubMed and manual bibliographic searches were conducted 
to identify relevant publications for oral and IV F. Studies were included if they were: 
1) published after January 1, 2000, 2) derived from human subjects, 3) written or 
translated in English 4) focused on CLL, and 5) evaluated efﬁcacy, resource utilization, 
complications, costs or patient preference. RESULTS: There were 17 articles that met 
inclusion criteria. Results indicated that the pharmacokinetic proﬁle of oral and IV F 
were similar, with 25 mg/m2 of IV being equivalent to 40 mg/m2 of oral. Oral F has 
similar efﬁcacy and safety to IV F, and eliminates infusion related adverse events and 
administration costs. Studies indicated that providing oral F was more convenient for 
patients and nurses due to the absence of IV administration. No cost or pharmaco-
economic data were found. CONCLUSIONS: Oral and IV F were found to have 
similar clinical efﬁcacy and safety. The oral formulation may potentially lead to 
substantial economic beneﬁts when factoring in possible reductions in infusion related 
administration and adverse events. Future studies need to compare real-world clinical 
outcomes and economic impact of oral vs. IV F, taking into account decision-making 
in clinical practice of both health care providers and patients.
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IMPACT OF 5-HT3-RECEPTOR ANTAGONIST STEP THERAPY ON 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING ASSOCIATED 
HOSPITAL AND EMERGENCY ROOM EVENTS
Hatoum HT1, Lin SJ2, Buchner D3, Cox D3, Powers A3
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OBJECTIVES: To explore the impact of step therapy policies requiring the use of a 
1st-generation 5-hydroxytryptamine- receptor antagonist (5-HT3-RA) treatment 
before palonosetron (a 2nd generation 5-HT3-RA) on the incremental risk of chemo-
therapy induced nausea and vomiting (CINV) associated with a hospital or emergency 
room (ER) event. METHODS: Claims data (PharMetrics) were used to identify con-
tinuously enrolled adult patients diagnosed with breast cancer (BC) and initiated on 
cyclophosphamide-based chemotherapy (CT) within 4 months post-diagnosis or with 
lung cancer (LC) and initiated on carboplatin-based CT. Patients were stratiﬁed into 
those initiated and maintained on palonosetron throughout CT (Group 1) versus those 
treated on day 1/cycle 1 with any other 5-HT3-RA regimen (Group 2). Risks and 
frequency for CINV-associated hospital or ER events identiﬁed through ICD-9-CM 
codes for nausea, vomiting, and/or dehydration during a 6-month follow-up period 
were estimated using logistic and Poisson regression models, controlling for age, 
gender (LC only), comorbidity, and CT days. RESULTS: Of 3606 BC and 4497 LC 
identiﬁed patients, 1864 BC (52%) and 1806 LC (40%) initiated palonosetron. 
Groups 1 and 2 had comparable comorbidity and CT treatment days. Compared to 
group 2 patients, group 1 patients had a signiﬁcantly lower probability of CINV-
associated hospital or ER events (3.5% vs. 5.5% in BC and 9.5% vs. 12.8% in LC), 
had 47.4% (BC) and 29.1% (LC) fewer hospital or ER days with CINV, and fewer 
5-HT3-RA claims (mean ± SD 6.2 ± 3.3 vs. 7.9 ± 4.1 in BC and 7.7 ± 4.9 vs. 10.3 ± 
6.4 in LC), all at p < 0.05. Risk for CINV was 38% (BC) and 29% (LC) lower for 
group 1 patients (Odds Ratio = 0.62 in BC and 0.71 in LC, p < 0.05). CONCLU-
SIONS: LC or BC patients initiated and maintained on palonosetron throughout CT 
were at signiﬁcantly lower risk for costly CINV versus those on any other 5-HT3-RA 
on day 1/cycle 1 of CT treatment.
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USING PROPENSITY SCORES TO REDUCE SELECTION BIAS IN AN 
OBSERVATIONAL STUDY COMPARING RASBURICASE TO 
ALLOPURINOL IN THE US
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BACKGROUND Randomized clinical trials remain the gold standard in evaluating 
different drug therapies on outcomes but are resource intensive. Retrospective studies 
using observational data are inexpensive but prone to selection bias due to non-ran-
dom differences between the intervention and comparator groups. The Propensity 
Score (PS) method is a novel, multivariate adjustment procedure that reduces con-
founding and selection bias. METHODS: This case-control study used the Health 
Facts® database (Cerner Corporation, Kansas City, MO), which integrates patient 
information from hospitals throughout the United States. Cancer patients receiving 
rasburicase or allopurinol were eligible for study inclusion. Both drugs reduce uric 
acid (UA) elevation otherwise resulting from tumor lysis syndrome. The PS is the 
